ASLNASLAN Pharmaceuticals Ltd

Nasdaq www.aslanpharma.com


$ 0.45 $ 0.01 (1.98 %)    

Friday, 17-May-2024 15:59:25 EDT
QQQ $ 451.63 $ -0.22 (-0.05 %)
DIA $ 399.76 $ 0.74 (0.19 %)
SPY $ 529.24 $ 0.76 (0.14 %)
TLT $ 91.40 $ -0.62 (-0.67 %)
GLD $ 223.63 $ 3.63 (1.65 %)
$ 0.4437
$ 0.44
$ 0.00 x 0
$ 0.00 x 0
$ 0.44 - $ 0.46
$ 0.39 - $ 4.40
177,329
na
54.18M
$ 1.74
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-aslan-pharma-maintains-9-price-target

HC Wainwright & Co. analyst Yi Chen reiterates ASLAN Pharma (NASDAQ:ASLN) with a Buy and maintains $9 price target.

 aslan-pharmaceuticals-announces-expansion-of-its-collaboration-with-zenyaku-to-investigate-the-biology-underlying-differential-effects-of-eblasakimab-compared-to-other-biologics

New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies ...

 hc-wainwright--co-reiterates-buy-on-aslan-pharma-maintains-9-price-target

HC Wainwright & Co. analyst Yi Chen reiterates ASLAN Pharma (NASDAQ:ASLN) with a Buy and maintains $9 price target.

 aslan-pharmaceuticals-reports-interim-results-from-phase-2-study-of-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients

https://www.sec.gov/Archives/edgar/data/1722926/000095017024046201/asln-ex99_1.htm 

 hc-wainwright--co-reiterates-buy-on-aslan-pharma-maintains-9-price-target

HC Wainwright & Co. analyst Yi Chen reiterates ASLAN Pharma (NASDAQ:ASLN) with a Buy and maintains $9 price target.

 hc-wainwright--co-maintains-buy-on-aslan-pharma-lowers-price-target-to-9

HC Wainwright & Co. analyst Yi Chen maintains ASLAN Pharma (NASDAQ:ASLN) with a Buy and lowers the price target from $17...

 piper-sandler-reiterates-overweight-on-aslan-pharma-lowers-price-target-to-10

Piper Sandler analyst Edward Tenthoff reiterates ASLAN Pharma (NASDAQ:ASLN) with a Overweight and lowers the price target fr...

 piper-sandler-maintains-overweight-on-aslan-pharma-lowers-price-target-to-10

Piper Sandler analyst Edward Tenthoff maintains ASLAN Pharma (NASDAQ:ASLN) with a Overweight and lowers the price target fro...

 piper-sandler-maintains-overweight-on-aslan-pharma-maintains-15-price-target

Piper Sandler analyst Edward Tenthoff maintains ASLAN Pharma (NASDAQ:ASLN) with a Overweight and maintains $15 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION